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Background
DNA vaccines have previously not been potent enough to
generate immunity in macaques, nor capable of impact-
ing a pathogenic SIV challenge. This study examines the
magnitude and phenotype of immune responses induced
by an optimized SIV vaccine delivered by electroporation
(EP) with or without plasmid IL-12 and the ability of
these responses to impact viral replication in a SIVmac251
challenge. The impact of macaque haplotypes on virus
control was also examined.
Methods
Two groups (n = 6) of Chinese rhesus macaques were
immunized with consensus SIVmacgag, env, and pol with
(DNA+12) or without (DNA) plasmid IL-12. All animals
were extensively haplotyped for potentially protective
alleles. Cellular responses were evaluated by IFN-γ ELIS-
pot, CFSE proliferation and ICS for polyfunctionality.
Animals were rested 8 months before an intra-rectal, high-
dose SIVmac251 challenge.
Results
Viral loads were followed out 35 weeks post-infection and
area under the curve analysis revealed that the DNA and
the DNA+12 group had a significant reduction in viral
loads over the course of the study compared to the naive
group (ANOVA: p = 0.035 and 0.037, respectively). A
more dramatic vaccine effect was seen early in infection,
at week 12, with the DNA+12 group having a 1.5 log
decrease in viral loads compared to the naive group. DNA
and DNA+12 immunization also prevented sustained
CD4+ T cell loss. Two animals in the DNA+12 group and
one in the DNA group had a MHC haplotype associated
with control. Interestingly, differences in viral loads in
these animals were not evident until late in infection and
no single immune parameter appeared to be consistently
enhanced in these controller animals.
Conclusion
This study demonstrates the efficacy of DNA vaccination
with plasmid IL-12 in impacting viral replication follow-
ing challenge. These data have clear importance for the
DNA vaccine platform as well as the T cell approach to
HIV vaccine development.
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